24 results on '"Vassal, G."'
Search Results
2. Evolution of the Innovative Therapies for Children With Cancer Consortium Trial Portfolio for Drug Development for Children With Cancer.
- Author
-
Bautista F, Verdú-Amorós J, Geoerger B, Rubio-San-Simón A, Paoletti X, Zwaan CM, Casanova M, Marshall LV, Carceller F, Doz F, Lecinse C, Vassal G, Pearson ADJ, Kearns P, and Moreno L
- Subjects
- Humans, Child, Adolescent, Clinical Trials, Phase II as Topic, Antineoplastic Agents therapeutic use, Clinical Trials, Phase I as Topic, Therapies, Investigational, Research Design, Neoplasms drug therapy, Drug Development
- Abstract
Purpose: The aim of the Innovative Therapies for Children with Cancer (ITCC) consortium is to improve access to novel therapies for children and adolescents with cancer. The evolution of the ITCC clinical trial portfolio since 2003 was reviewed., Methods: All ITCC-labeled phase I/II trials opened between January 1, 2003 and February 3, 2018 were analyzed in two periods (2003-2010 and 2011-2018), and data were extracted from the ITCC database, regulatory agencies' registries, and publications., Results: Sixty-one trials (62% industry-sponsored) enrolled 3,198 patients. The number of trials in the second period increased by almost 300% (16 v 45). All biomarker-driven trials (n = 14) were conducted in the second period. The use of rolling six and model-based designs increased (1 of 9, 11% v 21 of 31, 68%), and that of 3 + 3 designs decreased (5 of 9, 55% v 5 of 31, 16%; P = .014). The proportion of studies evaluating chemotherapeutics only decreased (5 of 16, 31% v 4 of 45, 9%), the proportion of single-agent targeted therapies did not change (9 of 16, 56.2% v 24 of 45, 53.3%), the proportion of combination targeted therapies trials increased (2 of 16, 12%, v 17 of 45, 38%), the proportion of randomized phase II trials increased (1 of 7, 14% v 8 of 14, 57%). More trials were part of a pediatric investigation plan in the second period (4 of 16, 25% v 21 of 45, 46%). The median time for Ethics Committees' approvals was 1.7 times longer for academic compared with industry-sponsored trials., Conclusion: This study reports a shift in the paradigm of early drug development for childhood cancers, with more biologically relevant targets evaluated in biomarker-driven trials or in combination with other therapies and with more model-based or randomized designs and a greater focus on fulfilling regulatory requirements. Improvement of trial setup and recruitment could increase the number of patients benefiting from novel agents.
- Published
- 2024
- Full Text
- View/download PDF
3. Chimeric Antigen Receptor (CAR) T-Cell Products for Pediatric Cancers: Why Alternative Development Paths Are Needed.
- Author
-
Rossig C, Pearson AD, Vassal G, Scobie N, Bird N, Blanc P, Vormoor HJ, Calkoen FG, Locatelli F, Del Bufalo F, Rives S, Jacoby E, Balduzzi A, Bourquin JP, and Baruchel A
- Subjects
- Child, Humans, Receptors, Antigen, T-Cell genetics, Receptors, Antigen, T-Cell therapeutic use, T-Lymphocytes, Immunotherapy, Adoptive, Receptors, Chimeric Antigen, Neoplasms therapy
- Published
- 2024
- Full Text
- View/download PDF
4. Combination Early-Phase Trials of Anticancer Agents in Children and Adolescents.
- Author
-
Moreno L, DuBois SG, Glade Bender J, Mauguen A, Bird N, Buenger V, Casanova M, Doz F, Fox E, Gore L, Hawkins DS, Izraeli S, Jones DTW, Kearns PR, Molenaar JJ, Nysom K, Pfister S, Reaman G, Smith M, Weigel B, Vassal G, Zwaan CM, Paoletti X, Iasonos A, and Pearson ADJ
- Subjects
- Adult, Child, Adolescent, Humans, Drug Development, Antineoplastic Agents adverse effects, Neoplasms drug therapy
- Abstract
Purpose: There is an increasing need to evaluate innovative drugs for childhood cancer using combination strategies. Strong biological rationale and clinical experience suggest that multiple agents will be more efficacious than monotherapy for most diseases and may overcome resistance mechanisms and increase synergy. The process to evaluate these combination trials needs to maximize efficiency and should be agreed by all stakeholders., Methods: After a review of existing combination trial methodologies, regulatory requirements, and current results, a consensus among stakeholders was achieved., Results: Combinations of anticancer therapies should be developed on the basis of mechanism of action and robust preclinical evaluation, and may include data from adult clinical trials. The general principle for combination early-phase studies is that, when possible, clinical trials should be dose- and schedule-confirmatory rather than dose-exploratory, and every effort should be made to optimize doses early. Efficient early-phase combination trials should be seamless, including dose confirmation and randomized expansion. Dose evaluation designs for combinations depend on the extent of previous knowledge. If not previously evaluated, limited evaluation of monotherapy should be included in the same clinical trial as the combination. Randomized evaluation of a new agent plus standard therapy versus standard therapy is the most effective approach to isolate the effect and toxicity of the novel agent. Platform trials may be valuable in the evaluation of combination studies. Patient advocates and regulators should be engaged with investigators early in a proposed clinical development pathway and trial design must consider regulatory requirements., Conclusion: An optimized, agreed approach to the design and evaluation of early-phase pediatric combination trials will accelerate drug development and benefit all stakeholders, most importantly children and adolescents with cancer.
- Published
- 2023
- Full Text
- View/download PDF
5. Prognostic Value of Neurotrophic Tyrosine Receptor Kinase Gene Fusions in Solid Tumors for Overall Survival: A Systematic Review and Meta-Analysis.
- Author
-
Lassen U, Bokemeyer C, Garcia-Foncillas J, Italiano A, Vassal G, Paracha N, Marian M, Chen Y, Linsell L, and Abrams K
- Subjects
- Adult, Child, Humans, Prognosis, Bayes Theorem, Retrospective Studies, Gene Fusion, Neoplasms diagnosis, Neoplasms genetics
- Abstract
Purpose: Evidence suggests that neurotrophic tyrosine receptor kinase ( NTRK ) gene fusions in solid tumors are predictive biomarkers for targeted inhibition across a number of adult and pediatric tumor types. However, despite robust clinical response to tyrosine receptor kinase (TRK) inhibitors, the natural history and prognostic implications of NTRK fusions in solid tumors are poorly understood. It is important to evaluate their prognostic significance on survival to provide some context to the clinical effectiveness observed in clinical trials of TRK-targeted therapies., Methods: A systematic literature review was conducted in Medline, Embase, Cochrane, and PubMed to identify studies comparing the overall survival (OS) of patients with NTRK fusion-positive ( NTRK +) versus NTRK fusion-negative ( NTRK -) tumors. Five retrospective matched case-control studies published before 11 August 2022 were assessed for inclusion, and three were selected for the meta-analysis (sample size: 69 NTRK +, 444 NTRK -). Risk of bias was assessed using the Risk of Bias Assessment tool for Non-randomized Studies tool. The pooled hazard ratio (HR) was estimated using a Bayesian random-effects model., Results: In the meta-analysis, the median follow-up ranged from 2 to 14 years and the median OS was between 10.1 and 12.7 months (where reported). Comparing patients with tumors NTRK + and NTRK -, the pooled HR estimate for OS was 1.51 (95% credible interval, 1.01 to 2.29). The patients analyzed had no previous or current exposure to TRK inhibitors., Conclusion: In patients not treated with TRK inhibitor therapies, those with NTRK + solid tumors have a 50% increased risk of mortality within 10 years from diagnosis or the start of standard therapy compared with those with NTRK - status. Although this is the most robust estimate of the comparative survival rate to date, further studies are required to reduce uncertainty.
- Published
- 2023
- Full Text
- View/download PDF
6. How Can Genomic Innovations in Pediatric Brain Tumors Transform Outcomes in Low- and Middle-Income Countries?
- Author
-
Bailey S, Davidson A, Parkes J, Tabori U, Figaji A, Epari S, Chinnaswamy G, Dias-Coronado R, Casavilca-Zambrano S, Amayiri N, Vassal G, Bouffet E, and Clifford SC
- Subjects
- Child, Genomics, Humans, Income, Brain Neoplasms genetics, Brain Neoplasms therapy, Developing Countries
- Published
- 2022
- Full Text
- View/download PDF
7. Reply to R. Lakhotia et al.
- Author
-
Burke GAA, Minard-Colin V, Aupérin A, Alexander S, Pillon M, Delgado R, Zsíros J, Uyttebroeck A, Dartigues P, Miles RR, Kazanowska B, Chiang AK, Haouy S, Bollard CM, Csoka M, Wheatley K, Barkauskas DA, Adamson PC, Vassal G, Patte C, and Gross TG
- Abstract
Competing Interests: G.A. Amos BurkeConsulting or Advisory Role: Roche (Inst), Janssen (Inst), Takeda (Inst), Oxford Immune Algorithmics, Novartis (Inst) Veronique Minard-ColinResearch Funding: Roche/Genentech (Inst), Bristol Myers Squibb/Pfizer (Inst) Anne AupérinConsulting or Advisory Role: MSD (Inst)Research Funding: F. Hoffmann-La Roche-Genentech (Inst) Anne UyttebroeckConsulting or Advisory Role: MSD Belgium & Luxembourg Catherine M. BollardLeadership: Cabaletta BioConsulting or Advisory Role: Mana Therapeutics, Catamaran Bio Keith WheatleyResearch Funding: Roche (Inst), Bio-Cancer Treatment International (Inst), EUSA Pharma (Inst), Bayer (Inst) Donald A. BarkauskasEmployment: Genentech (I)Stock and Other Ownership Interests: Genentech (I)Patents, Royalties, Other Intellectual Property: US patent based on PhD research in glioblastoma (I) Peter C. AdamsonEmployment: SanofiStock and Other Ownership Interests: Gilead Sciences, McKesson, Molina Healthcare, Thermo Fisher Scientific, UnitedHealthcare, AbbVie, Medtronic, SanofiOpen Payments Link: https://openpaymentsdata.cms.gov/physician/25275/summary Gilles VassalConsulting or Advisory Role: Bayer, Roche/Genentech, AstraZeneca, Bristol Myers Squibb, Lilly, Ipsen, NovartisTravel, Accommodations, Expenses: Bristol Myers Squibb, RocheNo other potential conflicts of interest were reported.
- Published
- 2022
- Full Text
- View/download PDF
8. Dose-Adjusted Etoposide, Doxorubicin, and Cyclophosphamide With Vincristine and Prednisone Plus Rituximab Therapy in Children and Adolescents With Primary Mediastinal B-Cell Lymphoma: A Multicenter Phase II Trial.
- Author
-
Burke GAA, Minard-Colin V, Aupérin A, Alexander S, Pillon M, Delgado R, Zsíros J, Uyttebroeck A, Dartigues P, Miles RR, Kazanowska B, Chiang AK, Haouy S, Bollard CM, Csoka M, Wheatley K, Barkauskas DA, Adamson PC, Vassal G, Patte C, and Gross TG
- Subjects
- Adolescent, Child, Cyclophosphamide administration & dosage, Dose-Response Relationship, Drug, Doxorubicin administration & dosage, Etoposide administration & dosage, Female, Follow-Up Studies, Humans, Lymphoma, Follicular pathology, Lymphoma, Large B-Cell, Diffuse pathology, Male, Mediastinal Neoplasms pathology, Prednisone administration & dosage, Prognosis, Prospective Studies, Rituximab administration & dosage, Vincristine administration & dosage, Antineoplastic Combined Chemotherapy Protocols therapeutic use, Lymphoma, Follicular drug therapy, Lymphoma, Large B-Cell, Diffuse drug therapy, Mediastinal Neoplasms drug therapy
- Abstract
Purpose: A dose-adjusted etoposide, doxorubicin, and cyclophosphamide with vincristine and prednisone plus rituximab (DA-EPOCH-R) regimen has been shown to deliver excellent survival for adults with primary mediastinal large B-cell lymphoma (PMLBL) without the use of radiotherapy. No international prospective evaluation of this regimen has previously been reported in children and adolescents., Patients and Methods: We conducted an international single-arm phase II trial involving patients younger than age 18 years with PMLBL who were to receive six courses of DA-EPOCH-R. The primary end point was event-free survival (EFS). Overall survival and toxicity were also assessed. This trial was registered (ClinicalTrials.gov identifier: NCT01516567)., Results: Analyses were based on 46 patients. The median age was 15.4 years (interquartile range: 14-16 years). The median follow-up was 59.0 months (interquartile range: 52.6-69.2 months). Fourteen events were observed (eight relapses or progressions (including three parenchymal CNS relapses), four residual lymphoma, and two second malignancies). The 4-year EFS was 69.6% (95% CI, 55.2 to 80.9), which did not differ from the rate observed historically ( P = .59). Seven deaths occurred (six disease-related and one second malignancy). The overall survival was 84.8% (95% CI, 71.8 to 92.4). Twenty-two patients (48%) reached dose levels ≥ 4. Nonhematologic adverse events grade ≥ 3 or cardiac adverse events grade ≥ 2 occurred in 47 of 276 (17%) courses and 30 of 46 patients (65%)., Conclusion: DA-EPOCH-R did not improve the EFS compared with a historical control in this first prospective multisite international study of children and adolescents with PMLBL. Further studies are required to determine the optimum therapy for children and adolescents with this lymphoma., Competing Interests: G. A. Amos BurkeConsulting or Advisory Role: Roche, Takeda, Oxford Immune Algorithmics, Novartis Veronique Minard-ColinResearch Funding: F. Hoffmann-La Roche-GenentechConsulting or Advisory Role: Novartis, Roche, BMS, Pfizer Anne AupérinConsulting or Advisory Role: MSDResearch Funding: F. Hoffmann-La Roche-Genentech Catherine M. BollardLeadership: Cabaletta BioConsulting or Advisory Role: Mana Therapeutics, Catamaran Bio Keith WheatleyResearch Funding: Bio-Cancer Treatment International, EUSA Pharma, Bayer Donald A. BarkauskasEmployment: Genentech (I)Stock and Other Ownership Interests: Genentech (I)Patents, Royalties, Other Intellectual Property: US patent on the basis of PhD research in glioblastoma (I) Peter C. AdamsonEmployment: SanofiStock and Other Ownership Interests: Gilead Sciences, McKesson, Molina Healthcare, Thermo Fisher Scientific, UnitedHealthcare, AbbVie, Medtronic, Sanofi Gilles VassalConsulting or Advisory Role: Bayer, Roche/Genentech, AstraZeneca, Bristol Myers Squibb, Lilly, Ipsen, NovartisTravel, Accommodations, Expenses: Bristol Myers Squibb, RocheNo other potential conflicts of interest were reported.
- Published
- 2021
- Full Text
- View/download PDF
9. Phase I or II Study of Ribociclib in Combination With Topotecan-Temozolomide or Everolimus in Children With Advanced Malignancies: Arms A and B of the AcSé-ESMART Trial.
- Author
-
Bautista F, Paoletti X, Rubino J, Brard C, Rezai K, Nebchi S, Andre N, Aerts I, De Carli E, van Eijkelenburg N, Thebaud E, Corradini N, Defachelles AS, Ducassou S, Morscher RJ, Vassal G, and Geoerger B
- Subjects
- Adolescent, Age Factors, Aminopyridines adverse effects, Aminopyridines pharmacokinetics, Antineoplastic Combined Chemotherapy Protocols adverse effects, Antineoplastic Combined Chemotherapy Protocols pharmacokinetics, Child, Child, Preschool, Cyclin-Dependent Kinase 4 antagonists & inhibitors, Cyclin-Dependent Kinase 4 genetics, Cyclin-Dependent Kinase 4 metabolism, Cyclin-Dependent Kinase 6 antagonists & inhibitors, Cyclin-Dependent Kinase 6 genetics, Cyclin-Dependent Kinase 6 metabolism, Everolimus adverse effects, Everolimus pharmacokinetics, Female, Humans, Infant, Male, Neoplasms enzymology, Neoplasms genetics, Neoplasms pathology, Protein Kinase Inhibitors adverse effects, Protein Kinase Inhibitors pharmacokinetics, Purines adverse effects, Purines pharmacokinetics, Temozolomide adverse effects, Temozolomide pharmacokinetics, Time Factors, Topotecan adverse effects, Topotecan pharmacokinetics, Treatment Outcome, Aminopyridines therapeutic use, Antineoplastic Combined Chemotherapy Protocols therapeutic use, Everolimus therapeutic use, Neoplasms drug therapy, Protein Kinase Inhibitors therapeutic use, Purines therapeutic use, Temozolomide therapeutic use, Topotecan therapeutic use
- Abstract
Purpose: AcSé-ESMART is a proof-of-concept, phase I or II, platform trial, designed to explore targeted agents in a molecularly enriched cancer population. Arms A and B aimed to define the recommended phase II dose and activity of the CDK4/6 inhibitor ribociclib with topotecan and temozolomide (TOTEM) or everolimus, respectively, in children with recurrent or refractory malignancies., Patients and Methods: Ribociclib was administered orally once daily for 16 days after TOTEM for 5 days (arm A) or for 21 days with everolimus orally once daily continuously in a 28-day cycle (arm B). Dose escalation followed the continuous reassessment method, and activity assessment the Ensign design. Arms were enriched on the basis of molecular alterations in the cell cycle or PI3K/AKT/mTOR pathways., Results: Thirty-two patients were included, 14 in arm A and 18 in arm B, and 31 were treated. Fourteen patients had sarcomas (43.8%), and 13 brain tumors (40.6%). Main toxicities were leukopenia, neutropenia, and lymphopenia. The recommended phase II dose was ribociclib 260 mg/m
2 once a day, temozolomide 100 mg/m2 once a day, and topotecan 0.5 mg/m2 once a day (arm A) and ribociclib 175 mg/m2 once a day and everolimus 2.5 mg/m2 once a day (arm B). Pharmacokinetic analyses confirmed the drug-drug interaction of ribociclib on everolimus exposure. Two patients (14.3%) had stable disease as best response in arm A, and seven (41.2%) in arm B, including one patient with T-acute lymphoblastic leukemia with significant blast count reduction. Alterations considered for enrichment were present in 25 patients (81%) and in eight of nine patients with stable disease; the leukemia exhibited CDKN2A/B and PTEN deficiency., Conclusion: Ribociclib in combination with TOTEM or everolimus was well-tolerated. The observed activity signals initiated a follow-up study of the ribociclib-everolimus combination in a population enriched with molecular alterations within both pathways., Competing Interests: Xavier PaolettiConsulting or Advisory Role: MSD Oncology, Daiichii Sankyo Jonathan RubinoResearch Funding: Roche/Genentech (Inst), Novartis (Inst), Bristol Myers Squibb/Celgene (Inst), Cyclacel (Inst), AstraZeneca (Inst), Taiho Oncology (Inst) Nicolas AndreResearch Funding: BMS (Inst)Travel, Accommodations, Expenses: BMS Isabelle AertsConsulting or Advisory Role: AstraZenecaTravel, Accommodations, Expenses: Jazz Pharmaceuticals Gilles VassalConsulting or Advisory Role: Bayer, Roche/Genentech, AstraZeneca, Bristol Myers Squibb, Lilly, Ipsen, NovartisTravel, Accommodations, Expenses: Bristol Myers Squibb, Roche Birgit GeoergerConsulting or Advisory Role: Roche/Genentech, Boehringer Ingelheim, Bayer, AZD, NovartisNo other potential conflicts of interest were reported.- Published
- 2021
- Full Text
- View/download PDF
10. NTRK Alterations in Pediatric High-Risk Malignancies Identified Through European Clinical Sequencing Programs Constitute Promising Drug Targets.
- Author
-
Pfaff E, Adam de Beaumais T, Marchais A, van Tilburg CM, Blattner-Johnson M, Dirksen U, Øra I, Geoerger B, Schleiermacher G, Pfister SM, Witt O, Jones DTW, and Vassal G
- Subjects
- Adolescent, Adult, Child, Child, Preschool, Female, Humans, Male, Precision Medicine methods, Sequence Analysis, DNA methods, Young Adult, Membrane Glycoproteins genetics, Neoplasms diagnosis, Neoplasms genetics, Receptor, trkA genetics, Receptor, trkB genetics, Receptor, trkC genetics
- Published
- 2021
- Full Text
- View/download PDF
11. Impact of Disease Evolution on Efficacy Outcomes From Larotrectinib in Patients With Locally Advanced or Metastatic Tropomyosin Receptor Kinase Fusion-Positive Solid Tumors.
- Author
-
Bokemeyer C, Vassal G, Italiano A, De La Cuesta E, Hiemeyer F, Fellous M, and Marian M
- Subjects
- Humans, Pyrazoles therapeutic use, Pyrimidines therapeutic use, Neoplasms drug therapy, Tropomyosin therapeutic use
- Abstract
Neurotrophic tyrosine receptor kinase ( NTRK ) gene fusions encode oncogenic, chimeric tropomyosin receptor kinase (TRK) proteins. Larotrectinib, an approved TRK inhibitor, is efficacious in locally advanced or metastatic (adv/met) TRK fusion cancer. We evaluated the time from initial diagnosis to locally advanced or metastatic disease and to initiation of larotrectinib treatment as well as larotrectinib impact on disease course., Materials and Methods: Patients were grouped by prior lines of therapy (0, 1-2, and ≥ 3) and pre-larotrectinib duration of adv/met disease (short [< 3.5 months], medium [3.5 to < 15.7 months], and long [≥ 15.7 months]). Overall response rate (ORR), duration of response (DOR), and progression-free survival were assessed., Results: One hundred sixty-four patients were evaluated. The median time from initial diagnosis to development of locally adv/met stage was 2.1 months; the duration of pre-larotrectinib adv/met disease was 7.3 months (n = 153). In patients with 0, 1-2, and ≥ 3 prior lines of therapy, the median time from diagnosis to adv/met stage was 0.9, 1.2, and 9.4 months, and 1.5, 5.8, and 29.0 months from adv/met disease to larotrectinib initiation, respectively. Clinical outcomes were independent of line of therapy (ORR: 86%, 63%, and 80%, respectively; median DOR: 27.6, not reached, and 32.9 months), and similar across subgroups of short, medium, and long duration of pre-larotrectinib adv/met disease status (ORR: 88%, 65%, and 69%, respectively; median DOR: not reached, 27.6, and 32.9 months)., Conclusion: The short time from initial diagnosis to adv/met stage before larotrectinib suggests that NTRK gene fusion does not generally have a positive prognostic value. Patients on larotrectinib had high, sustained ORR, independent of number of prior therapies or duration of adv/met disease, suggesting that the effect of TRK inhibition in molecularly selected patients is independent of prior treatments or disease course., Competing Interests: Marisca Marian Employment: Bayer No other potential conflicts of interest were reported. Marisca Marian Employment: Bayer No other potential conflicts of interest were reported., (© 2021 by American Society of Clinical Oncology.)
- Published
- 2021
- Full Text
- View/download PDF
12. Crossing Oceans: Preclinical Collaboration to Improve Pediatric Drug Development.
- Author
-
Reaman G, Stancato L, Vassal G, and Maris JM
- Subjects
- Child, Humans, Drug Development
- Abstract
Changes in the regulatory environment affecting pediatric cancer drug development in the United States and the European Union provide unprecedented opportunity to advance the concept of precision medicine to children with cancer. Increasing evidence suggests that new drugs and biologic products directed at molecular targets presumed to be etiologically associated with many adult cancers may well provide therapeutic options for selected subsets of children with cancer despite their histologic and biologic differences. Regulatory requirements for early evaluation of appropriate new drugs for children based on their molecular mechanism of action, rather than the specific clinical indications for which they are developed and/or approved, will shorten the unacceptable time lag between first-in-human and first-in-children studies. The relative scarcity of pediatric patients eligible for biomarker-directed studies and the ever-expanding compendium of new targeted agents mandate rational, science-based decision-making in selecting and prioritizing appropriate drugs to study early in development. A critical component of the evidence base in such decision-making includes preclinical testing of relevant drugs in pediatric tumor-specific in vitro and in vivo models. Established preclinical testing programs with academic investigator-industry collaborations are actively engaged in such activities. International collaboration is required to address the resource constraints and increasing number of potential products to be tested in a timely, efficient, nonduplicative, and cost-effective manner.
- Published
- 2020
- Full Text
- View/download PDF
13. Real-World Utility of an Amplicon-Based Next-Generation Sequencing Liquid Biopsy for Broad Molecular Profiling in Patients With Advanced Non-Small-Cell Lung Cancer.
- Author
-
Remon J, Lacroix L, Jovelet C, Caramella C, Howarth K, Plagnol V, Rosenfeld N, Morris C, Mezquita L, Pannet C, Ngocamus M, Le Pechoux C, Adam J, Grecea AM, Planchard D, Vassal G, Benitez JC, Gazzah A, Green E, Soria JC, and Besse B
- Abstract
Purpose: To assess the feasibility and utility of circulating tumor DNA (ctDNA) by amplicon-based next-generation sequencing (NGS) analysis in the daily clinical setting in a cohort of patients with advanced non-small-cell lung cancer (NSCLC), as an alternative approach to tissue molecular profiling., Patients and Methods: In this single-center prospective study, treatment-naïve and previously treated patients with advanced NSCLC were enrolled. Clinical validation of ctDNA using amplicon-based NGS analysis (with a 36-gene panel) was performed against standard-of-care tissue molecular analysis in treatment-naïve patients. The feasibility, utility, and prognostic value of ctDNA as a dynamic marker of treatment efficacy was evaluated. Results of tissue molecular profile were blinded during ctDNA analysis., Results: Of 214 patients with advanced NSCLC who were recruited, 156 were treatment-naïve patients and 58 were pretreated patients with unknown tissue molecular profile. ctDNA screening was successfully performed for 91% (n = 194) of all patients, and mutations were detected in 77% of these patients. Tissue molecular analysis was available for 111 patients (52%), and tissue somatic mutations were found for 78% (n = 87) of patients. For clinically relevant variants, concordance agreement between ctDNA and tumor tissue analysis was 95% among 94 treatment-naïve patients who had concurrent liquid and tumor biopsy molecular profiles. Sensitivity and specificity were 81% and 97%, respectively. Of the 103 patients with no tissue available, ctDNA detected potential actionable mutations in 17% of patients; of these, 10% received personalized treatment. ctDNA kinetics correlated with response rate and progression-free survival in 31 patients treated with first-line platinum-based chemotherapy., Conclusion: These real-world data from a prospective study endorse ctDNA molecular profile by amplicon-based NGS as an accurate and reliable tool to detect and monitor clinically relevant molecular alterations in patients with advanced NSCLC., Competing Interests: The following represents disclosure information provided by authors of this manuscript. All relationships are considered compensated. Relationships are self-held unless noted. I = Immediate Family Member, Inst = My Institution. Relationships may not relate to the subject matter of this manuscript. For more information about ASCO's conflict of interest policy, please refer to www.asco.org or ascopubs.org/po/author-center.Jordi RemonConsulting or Advisory Role: Pfizer, Bristol-Myers Squibb, Boehringer Ingelheim, MSD Oncology Travel, Accommodations, Expenses: Roche, Genentech, Inivata, OSE ImmunotherapeuticsCaroline CaramellaConsulting or Advisory Role: Bristol-Myers Squibb, PfizerKaren HowarthEmployment: Inivata Stock and Other Ownership Interests: Inivata Research Funding: Inivata Patents, Royalties, Other Intellectual Property: Patents and patent applications relating to cancer classifications, detection or analysis of microRNA and circulating tumor DNA, detection of rare sequence variants, applications in molecular diagnosticsVincent PlagnolEmployment: Inivata Stock and Other Ownership Interests: Inivata Patents, Royalties, Other Intellectual Property: Inivata patentsNitzan RosenfeldEmployment: Storm Therapeutics (I), Inivata Leadership: Inivata Stock and Other Ownership Interests: Inivata, Mission Therapeutics (I) Research Funding: AstraZeneca (Inst) Patents, Royalties, Other Intellectual Property: Patents and patent applications relating to cancer classifications, detection or analysis of microRNA and circulating tumor DNA, detection of rare sequence variants, applications in molecular diagnosticsClive MorrisEmployment: Inivata Leadership: Inivata Stock and Other Ownership Interests: InivataCecile Le PechouxConsulting or Advisory Role: AstraZeneca, Lilly, Nanobiotix, AmgenJulien AdamConsulting or Advisory Role: Roche, Bristol-Myers Squibb, AstraZeneca, Merck Sharp & Dohme Research Funding: Sanofi (Inst), Pierre Fabre (Inst), Merck Sharp & Dohme (Inst)David PlanchardConsulting or Advisory Role: AstraZeneca, Boehringer Ingelheim, Bristol-Myers Squibb, Novartis, Roche, Pfizer, MSD Oncology, CelgeneGilles VassalConsulting or Advisory Role: Bayer, Roche, Genentech, AstraZeneca, Bristol-Myers Squibb, Celgene, Lilly, Servier, Takeda, Incyte, Ipsen, Novartis, Merck Serono Travel, Accommodations, Expenses: Bristol-Myers Squibb, RocheEmma GreenEmployment: Inivata Stock and Other Ownership Interests: Inivata Travel, Accommodations, Expenses: InivataJean-Charles SoriaEmployment: MedImmune Stock and Other Ownership Interests: AstraZeneca, Gritstone Oncology Honoraria: Roche, AstraZeneca, Sanofi, Servier, Pierre Fabre, Abbvie, Pharmamar-ZeltiaBenjamin BesseResearch Funding: AstraZeneca (Inst), Roche (Inst), Genentech (Inst), Pfizer (Inst), Boehringer Ingelheim (Inst), Lilly (Inst), Servier (Inst), Onxeo (Inst), Bristol-Myers Squibb (Inst), Ose Pharma (Inst), Inivata (Inst), Novartis (Ins), OncoMed (Inst), Loxo (Inst) Travel, Accommodations, Expenses: Roche, Pfizer, Bristol-Myers Squibb, Medarex, Novartis, Pierre Fabre No other potential conflicts of interest were reported., (© 2019 by American Society of Clinical Oncology.)
- Published
- 2019
- Full Text
- View/download PDF
14. Phase II, Open-Label, Randomized, Multicenter Trial (HERBY) of Bevacizumab in Pediatric Patients With Newly Diagnosed High-Grade Glioma.
- Author
-
Grill J, Massimino M, Bouffet E, Azizi AA, McCowage G, Cañete A, Saran F, Le Deley MC, Varlet P, Morgan PS, Jaspan T, Jones C, Giangaspero F, Smith H, Garcia J, Elze MC, Rousseau RF, Abrey L, Hargrave D, and Vassal G
- Subjects
- Adolescent, Antineoplastic Combined Chemotherapy Protocols adverse effects, Bevacizumab administration & dosage, Bevacizumab adverse effects, Cerebellar Neoplasms pathology, Cerebellar Neoplasms radiotherapy, Cerebellar Neoplasms surgery, Chemoradiotherapy, Adjuvant, Child, Child, Preschool, Female, Glioma pathology, Glioma radiotherapy, Glioma surgery, Humans, Male, Neoplasm Grading, Progression-Free Survival, Temozolomide administration & dosage, Temozolomide adverse effects, Antineoplastic Combined Chemotherapy Protocols therapeutic use, Cerebellar Neoplasms drug therapy, Glioma drug therapy
- Abstract
Purpose Bevacizumab (BEV) is approved in more than 60 countries for use in adults with recurrent glioblastoma. We evaluated the addition of BEV to radiotherapy plus temozolomide (RT+TMZ) in pediatric patients with newly diagnosed high-grade glioma (HGG). Methods The randomized, parallel group, multicenter, open-label HERBY trial ( ClinicalTrials.gov identifier: NCT01390948) enrolled patients age ≥ 3 years to ≤ 18 years with localized, centrally neuropathology-confirmed, nonbrainstem HGG. Eligible patients were randomly assigned to receive RT + TMZ (RT: 1.8 Gy, 5 days per week, and TMZ: 75 mg/m
2 per day for 6 weeks; 4-week treatment break; then up to 12 × 28-day cycles of TMZ [cycle 1: 150 mg/m2 per day, days 1 to 5; cycles 2 to 12: 200 mg/m2 per day, days 1 to 5]) with or without BEV (10 mg/kg every 2 weeks). The primary end point was event-free survival (EFS) as assessed by a central radiology review committee that was blinded to treatment. We report findings of EFS at 12 months after the enrollment of the last patient. Results One hundred twenty-one patients were enrolled (RT+TMZ [n = 59]; BEV plus RT+TMZ [n = 62]). Central radiology review committee-assessed median EFS did not differ significantly between treatment groups (RT+TMZ, 11.8 months; 95% CI, 7.9 to 16.4 months; BEV plus RT+TMZ, 8.2 months; 95% CI, 7.8 to 12.7 months; hazard ratio, 1.44; P = .13 [stratified log-rank test]). In the overall survival analysis, the addition of BEV did not reduce the risk of death (hazard ratio, 1.23; 95% CI, 0.72 to 2.09). More patients in the BEV plus RT+TMZ group versus the RT+TMZ group experienced one or more serious adverse events (n = 35 [58%] v n = 27 [48%]), and more patients who received BEV discontinued study treatment as a result of adverse events (n = 13 [22%] v n = 3 [5%]). Conclusion Adding BEV to RT+TMZ did not improve EFS in pediatric patients with newly diagnosed HGG. Our findings were not comparable to those of previous adult trials, which highlights the importance of performing pediatric-specific studies.- Published
- 2018
- Full Text
- View/download PDF
15. Candidate genes on chromosome 9q33-34 involved in the progression of childhood ependymomas.
- Author
-
Puget S, Grill J, Valent A, Bieche I, Dantas-Barbosa C, Kauffmann A, Dessen P, Lacroix L, Geoerger B, Job B, Dirven C, Varlet P, Peyre M, Dirks PB, Sainte-Rose C, and Vassal G
- Subjects
- Adolescent, Child, Child, Preschool, Disease Progression, Female, Humans, Infant, Infratentorial Neoplasms genetics, Male, Mutation, Nucleic Acid Hybridization, Receptors, Notch genetics, Tenascin genetics, Young Adult, Brain Neoplasms genetics, Chromosomes, Human, Pair 9 genetics, Ependymoma genetics, Neoplasm Recurrence, Local genetics
- Abstract
Purpose: The molecular pathogenesis of pediatric ependymoma remains unclear. Our study was designed to identify genetic changes implicated in ependymoma progression., Patients and Methods: We characterized 59 ependymoma samples (33 at diagnosis and 26 at relapse) using array-comparative genomic hybridization (aCGH). Specific chromosomal imbalances were confirmed by fluorescent in situ hybridization, and candidate genes were assessed by real-time quantitative polymerase chain reaction (qPCR), immunohistochemistry, sequencing, and in vitro functional studies., Results: aCGH analysis revealed a significant increase in genomic imbalances on relapse compared with diagnosis, such as gain of 9qter and 1q (54% v 21% and 12% v 0%, respectively) and loss of 6q (27% v 6%). Supervised tumor classification showed that gain of 9qter was associated with tumor recurrence, age older than 3 years, and posterior fossa location. Using a candidate-gene strategy, we found an overexpression of two potential oncogenes at the locus 9qter: Tenascin-C and Notch1. Moreover, Notch pathway analysis (qPCR) revealed overexpression of Notch ligands, receptors, and target genes (Hes-1, Hey2, and c-Myc), and downregulation of Notch repressor Fbxw7. We confirmed by immunohistochemistry the overexpression of Tenascin-C and Hes-1. We detected Notch1 missense mutations in 8.3% of the tumors (only in the posterior fossa location and in case of 9q33-34 gain). Furthermore, inhibition of Notch pathway with a gamma-secretase inhibitor impaired the growth of ependymoma stem cell cultures., Conclusion: The activation of the Notch pathway and Tenascin-C seem to be important events in ependymoma progression and may represent future targets for therapy. We report, to our knowledge for the first time, recurrent oncogenic mutations in pediatric posterior fossa ependymomas.
- Published
- 2009
- Full Text
- View/download PDF
16. Phase II trial of irinotecan in children with relapsed or refractory rhabdomyosarcoma: a joint study of the French Society of Pediatric Oncology and the United Kingdom Children's Cancer Study Group.
- Author
-
Vassal G, Couanet D, Stockdale E, Geoffray A, Geoerger B, Orbach D, Pichon F, Gentet JC, Picton S, Bergeron C, Cisar L, Assadourian S, and Morland B
- Subjects
- Adolescent, Adult, Antineoplastic Agents, Phytogenic administration & dosage, Antineoplastic Agents, Phytogenic adverse effects, Camptothecin administration & dosage, Camptothecin adverse effects, Camptothecin therapeutic use, Child, Child, Preschool, Disease Progression, Drug Administration Schedule, Female, Humans, Infant, Irinotecan, Male, Rhabdomyosarcoma pathology, Survival Analysis, Treatment Outcome, Antineoplastic Agents, Phytogenic therapeutic use, Camptothecin analogs & derivatives, Neoplasm Recurrence, Local drug therapy, Rhabdomyosarcoma drug therapy
- Abstract
Purpose: This phase II study was designed to evaluate the efficacy of irinotecan administered intravenously once every 3 weeks in pediatric patients with recurrent or refractory rhabdomyosarcoma., Patients and Methods: A total of 35 patients younger than age 20 years, with refractory or relapsed rhabdomyosarcoma for which standard treatments have failed, received irinotecan at 600 mg/m2 administered as a 60-minute infusion every 3 weeks. Concomitant treatments included atropine for cholinergic symptoms, loperamide for diarrhea at the first liquid stool, and preventive antiemetic treatment. Tumor response was assessed every two cycles until progression according to WHO criteria., Results: The best overall response rate to irinotecan was 11.4% (95% CI, 3.2 to 26.7%; 2.9% complete responses, 8.5% partial responses) from all patients recruited. The median times to progression and survival were 1.4 and 5.8 months, respectively. A total of 112 cycles were administered, with a median number of two cycles per patient (range, 1 to 16). The most common grade 3/4 toxicities were neutropenia (46%), abdominal pain or cramping (17%), cholinergic syndrome (14%), nausea/vomiting (11%), anemia (11%), thrombocytopenia (9%), and diarrhea (6%)., Conclusion: In heavily pretreated children with a high tumor burden who have been treated with multiagent chemotherapy, irinotecan administered intravenously as a single agent, at 600 mg/m2 every 3 weeks, showed an interesting objective response rate and a good tolerance profile in rhabdomyosarcoma.
- Published
- 2007
- Full Text
- View/download PDF
17. Phase II study of temozolomide in relapsed or refractory high-risk neuroblastoma: a joint Société Française des Cancers de l'Enfant and United Kingdom Children Cancer Study Group-New Agents Group Study.
- Author
-
Rubie H, Chisholm J, Defachelles AS, Morland B, Munzer C, Valteau-Couanet D, Mosseri V, Bergeron C, Weston C, Coze C, Auvrignon A, Djafari L, Hobson R, Baunin C, Dickinson F, Brisse H, McHugh K, Biassoni L, Giammarile F, and Vassal G
- Subjects
- Adolescent, Antineoplastic Agents, Alkylating administration & dosage, Antineoplastic Agents, Alkylating adverse effects, Bone Marrow drug effects, Child, Child, Preschool, Dacarbazine administration & dosage, Dacarbazine adverse effects, Dacarbazine therapeutic use, Female, France, Humans, Infant, Male, Temozolomide, Thrombocytopenia chemically induced, Treatment Outcome, United Kingdom, Antineoplastic Agents, Alkylating therapeutic use, Dacarbazine analogs & derivatives, Neuroblastoma drug therapy
- Abstract
Purpose: To determine the response rate (RR) of neuroblastoma (NB) in children to temozolomide (TMZ), and evaluate the duration of response and tolerance of the drug in this patient population., Patients and Methods: A multicenter, phase II evaluation of an oral, daily schedule of TMZ (200 mg/m2/d x 5 days every 28 days) was undertaken in children with refractory or relapsed high-risk NB (metastatic or localized with Myc-N amplification). Response assessment was based on imaging with two-dimentional measurement of disease and meta-iodobenzylguanidine (MIBG) score. Activity was defined by a reduction in lesion size or isotope uptake at anytime. Methodology included a two-step design using Fleming's method with a first step of 15 patients and a second of 10 additional patients if two to four responses had been observed in the first cohort. All data was centrally reviewed by a panel., Results: Twenty-five assessable patients were recruited over a 14-month period in 14 centers and received 94 cycles of chemotherapy. Twenty-three patients had metastatic NB either refractory (n = 9) or in relapse (n = 14). Grade 3 or 4 thrombocytopenia was the most frequent toxicity (16% of cycles). Myelosuppression resulted in treatment delays and dose reductions (24% and 21% of cycles, respectively). Response (complete response, very good partial response, or partial response) was observed in five patients (RR = 20% +/- 8%) with a median duration of 6 months and an objective or mixed response in five additional patients., Conclusion: Temozolomide shows activity in heavily pretreated patients with NB, and deserves further evaluation in combination with another drug.
- Published
- 2006
- Full Text
- View/download PDF
18. A phase I study of irinotecan as a 3-week schedule in children with refractory or recurrent solid tumors.
- Author
-
Vassal G, Doz F, Frappaz D, Imadalou K, Sicard E, Santos A, O'Quigley J, Germa C, Risse ML, Mignard D, and Pein F
- Subjects
- Adolescent, Antineoplastic Agents, Phytogenic, Camptothecin administration & dosage, Camptothecin pharmacokinetics, Camptothecin toxicity, Child, Preschool, Drug Administration Schedule, Humans, Infant, Infusions, Intravenous, Irinotecan, Maximum Tolerated Dose, Neutropenia chemically induced, Camptothecin analogs & derivatives, Camptothecin therapeutic use, Neoplasms drug therapy
- Abstract
Purpose: A phase I study was performed to determine the maximum-tolerated dose (MTD) and safety profile of irinotecan (CPT-11) administered as a single intravenous infusion every 3 weeks in children with recurrent or refractory solid tumors., Patients and Methods: Eighty-one patients were enrolled, including 48 less heavily, and 33 heavily pretreated patients (cranial irradiation and/or high-dose chemotherapy). Children received CPT-11 as a 120-minute infusion at doses ranging from 200 to 720 mg/m2. The dose-limiting toxicities (DLT) on first cycle were determined in both cohorts., Results: One hundred twenty-two cycles and 81 cycles were administered in less heavily, and heavily pretreated patients, respectively. The primary DLT was delayed diarrhea in less heavily pretreated patients, and neutropenia in heavily pretreated patients. MTD was 600 mg/m2 in both cohorts. Grade 3 to 4 neutropenia occurred in 33% and 38% of cycles in less heavily, and heavily pretreated patients, respectively. Grade 3 to 4 nonhematologic toxicities included nausea/vomiting (7% and 4% of cycles in less heavily, and heavily pretreated patients, respectively), asthenia (7% and 4% of cycles, respectively), and delayed diarrhea (6% and 2.5% of cycles, respectively). Four partial responses at 600 mg/m2 (high-grade glioma, neuroblastoma, medulloblastoma, and rhabdomyosarcoma) and 21 minor responses and stable diseases were observed. Pharmacokinetic analysis of CPT-11 and SN-38 was performed in 77 patients. The mean +/- standard deviation (SD) CPT-11 plasma clearance was 20.7 +/- 9.5 L/h/m2 (range, 5 to 54). The mean +/- SD SN-38 metabolic ratio was 1.5% +/- 1.1% (range, 0.15% to 5.55%)., Conclusion: The recommended phase II dose of CPT-11 in a 3-week schedule is 600 mg/m2 in less heavily, and heavily pretreated children with solid tumors.
- Published
- 2003
- Full Text
- View/download PDF
19. Risk of secondary leukemia after a solid tumor in childhood according to the dose of epipodophyllotoxins and anthracyclines: a case-control study by the Société Française d'Oncologie Pédiatrique.
- Author
-
Le Deley MC, Leblanc T, Shamsaldin A, Raquin MA, Lacour B, Sommelet D, Chompret A, Cayuela JM, Bayle C, Bernheim A, de Vathaire F, Vassal G, and Hill C
- Subjects
- Adolescent, Adult, Antibiotics, Antineoplastic administration & dosage, Antineoplastic Agents, Phytogenic administration & dosage, Case-Control Studies, Chemotherapy, Adjuvant, Child, Child, Preschool, Drug Administration Schedule, Etoposide administration & dosage, Female, France, Humans, Leukemia chemically induced, Male, Multivariate Analysis, Neoplasms, Second Primary chemically induced, Radiotherapy, Adjuvant, Risk Assessment, Risk Factors, Antibiotics, Antineoplastic adverse effects, Antineoplastic Agents, Phytogenic adverse effects, Bone Marrow radiation effects, Etoposide adverse effects, Leukemia etiology, Neoplasms drug therapy, Neoplasms radiotherapy, Neoplasms, Second Primary etiology
- Abstract
Purpose: To estimate the risk of secondary leukemia as a function of the dose of epipodophyllotoxins and anthracyclines., Methods: We conducted a case-control study of the risk of secondary leukemia or myelodysplasia after a solid tumor in childhood within the Société Française d'Oncologie Pédiatrique, including 61 patients with leukemia matched with 196 controls. The characteristics of the first cancer, the patient's family history of cancer, and the treatment (type, cumulative dose of chemotherapy, schedule of etoposide administration, and radiation dose delivered to active bone marrow) were compared in the two groups., Results: Only two factors were found to increase the risk of leukemia in multivariate analysis, namely, the type of the first tumor, with an excess risk in patients with Hodgkin's disease (relative risk 6.4; 95% confidence interval [CI], 1.6 to 24) or osteosarcoma (relative risk 5; 95% CI, 1.3 to 19), and exposure to epipodophyllotoxins and anthracyclines. The risk of leukemia increased regularly with the cumulative dose of etoposide. In summary, patients who received between 1.2 and 6 g/m(2) of epipodophyllotoxins or more than 170 mg/m(2) of anthracyclines had a seven-fold higher risk (95% CI, 2.6 to 19) compared with patients who received lower doses or none of these drugs. The risk of leukemia in patients who received more than 6 g/m(2) of epipodophyllotoxins was multiplied by 197 (95% CI, 19 to 2,058). The risk of leukemia was not increased by exposure to alkylating agents or radiotherapy., Conclusion: Both epipodophyllotoxins and anthracyclines increase the risk of secondary leukemia. The current challenge is to minimize the mutagenic effects of these drugs by diminishing cumulative doses without losing the therapeutic benefits.
- Published
- 2003
- Full Text
- View/download PDF
20. Temozolomide in malignant gliomas of childhood: a United Kingdom Children's Cancer Study Group and French Society for Pediatric Oncology Intergroup Study.
- Author
-
Lashford LS, Thiesse P, Jouvet A, Jaspan T, Couanet D, Griffiths PD, Doz F, Ironside J, Robson K, Hobson R, Dugan M, Pearson AD, Vassal G, and Frappaz D
- Subjects
- Adolescent, Antineoplastic Agents, Alkylating administration & dosage, Antineoplastic Agents, Alkylating adverse effects, Bone Marrow drug effects, Child, Child, Preschool, Dacarbazine administration & dosage, Dacarbazine adverse effects, Female, Humans, Male, Temozolomide, Thrombocytopenia chemically induced, Antineoplastic Agents, Alkylating therapeutic use, Brain Neoplasms drug therapy, Dacarbazine analogs & derivatives, Dacarbazine therapeutic use, Glioma drug therapy
- Abstract
Purpose: To determine the response rate of the malignant gliomas of childhood to an oral, daily schedule of temozolomide., Patients and Methods: A multicenter, phase II evaluation of an oral, daily schedule of temozolomide (200 mg/m(2) on 5 consecutive days) was undertaken in children with relapsed or progressive, biopsy-proven, high-grade glioma (arm A) and progressive, diffuse, intrinsic brainstem glioma (arm B). Evidence of activity was defined by radiologic evidence of a sustained reduction in tumor size on serial magnetic resonance imaging scans., Results: Fifty-five patients were recruited (34 to arm A and 21 to arm B) and received 215 cycles of chemotherapy. Grade 3/4 thrombocytopenia was the most frequent toxic event (7% of cycles). Prolonged myelosuppression resulted in significant treatment delays and dose reductions (17% and 22% of cycles, respectively). Two toxic deaths were documented and were related to myelosuppression and sepsis in one patient and pneumonia in a second. The overall (best) response rate was 12% for arm A (95% confidence interval [CI], 3 to 28 in the study cohort, and 2 to 31 for eligible patients) and 5% and 6%, respectively, for arm B (95% CI, 0 to 26 in the study cohort, and 0 to 27 for eligible patients). Stabilization of disease was also documented and was most noteworthy for brainstem gliomas, where two patients achieved both radiologic static disease and discontinued steroid medication., Conclusion: Despite moderate toxicity, objective response rates to temozolomide have been low, indicating that temozolomide has minimal activity in the high-grade gliomas of childhood.
- Published
- 2002
- Full Text
- View/download PDF
21. Pathophysiology and therapy of irinotecan-induced delayed-onset diarrhea in patients with advanced colorectal cancer: a prospective assessment.
- Author
-
Saliba F, Hagipantelli R, Misset JL, Bastian G, Vassal G, Bonnay M, Herait P, Cote C, Mahjoubi M, Mignard D, and Cvitkovic E
- Subjects
- Adult, Aged, Antineoplastic Agents, Phytogenic therapeutic use, Camptothecin adverse effects, Camptothecin therapeutic use, Diarrhea drug therapy, Diarrhea physiopathology, Female, Humans, Irinotecan, Loperamide adverse effects, Loperamide therapeutic use, Male, Middle Aged, Prospective Studies, Thiorphan adverse effects, Thiorphan analogs & derivatives, Thiorphan pharmacokinetics, Thiorphan therapeutic use, Antidiarrheals therapeutic use, Antineoplastic Agents, Phytogenic adverse effects, Camptothecin analogs & derivatives, Colorectal Neoplasms drug therapy, Diarrhea chemically induced
- Abstract
Purpose: Irinotecan (CPT-11), a camptothecin derivative, has shown efficacy against colorectal cancer. Delayed-onset diarrhea is its main limiting toxicity. The aim of this study was to determine the pathophysiology of CPT-11-induced delayed-onset diarrhea and assess the efficacy of combined antidiarrheal medication in a phase II, prospective, successive-cohorts, open study., Patients and Methods: Twenty-eight patients with advanced colorectal cancer refractory to fluorouracil (5-FU) therapy received CPT-11 350 mg/m2 every 3 weeks. The first cohort of 14 consecutive patients explored for the mechanism of diarrhea received acetorphan (a new enkephalinase inhibitor) 100 mg three times daily; the second 14-patient cohort received, in addition to acetorphan, loperamide 4 mg three times daily. Before treatment, and if late diarrhea occurred, patients underwent colon mucosal biopsies for CPT-11 and topoisomerase I levels; intestinal transit time; fecalogram; fat and protein excretion; alpha1-antitrypsin clearance; D-xylose test; blood levels for vasoactive intestinal polypeptide, glucagon, gastrin, somatostatin, prostaglandin E2, and carboxylesterase; CPT-11/SN-38 and SN-38 glucuronide pharmacokinetics; and stool cultures., Results: Delayed-onset diarrhea occurred during the first three treatment cycles in 23 patients (82%). Electrolyte fecal measurements showed a negative or small osmotic gap in nine of nine patients and an increased alpha1-antitrypsin clearance in six of six patients. There were no modifications in stool cultures or hormonal dysfunction. Four of 11 patients (36%) with delayed-onset diarrhea in the first cohort responded to acetorphan, whereas nine of 10 patients (90%) responded to the combination of acetorphan and loperamide (P < .02)., Conclusion: CPT-11-induced delayed-onset diarrhea is caused by a secretory mechanism with an exudative component. Early combined treatment with loperamide and acetorphan seems effective in controlling the diarrheal episodes.
- Published
- 1998
- Full Text
- View/download PDF
22. Conduct of phase I trials in children with cancer.
- Author
-
Smith M, Bernstein M, Bleyer WA, Borsi JD, Ho P, Lewis IJ, Pearson A, Pein F, Pratt C, Reaman G, Riccardi R, Seibel N, Trueworthy R, Ungerleider R, Vassal G, and Vietti T
- Subjects
- Antineoplastic Agents administration & dosage, Antineoplastic Agents pharmacokinetics, Child, Child, Preschool, Guidelines as Topic, Humans, Infant, Antineoplastic Agents therapeutic use, Clinical Trials, Phase I as Topic standards, Neoplasms therapy
- Abstract
Purpose and Methods: Future progress in the care of children with cancer requires appropriate evaluations of promising new agents for pediatric indications, beginning with well-conducted phase I trials. This report summarizes current guidelines for the conduct of pediatric phase I trials and represents a consensus between American and European investigators. The primary objective of pediatric phase I trials is to define safe and appropriate doses and schedules of new agents that can subsequently be used in phase II trials to test for activity against specific childhood malignancies. Prioritization of agents for evaluation in children is critical, since many more investigational agents are evaluated in adult patients than can be systematically evaluated in children. Considerations used in prioritizing agents include activity in xenograft models, novel mechanism of action, favorable drug-resistance profile, and activity observed in adult trials of the agent., Results and Conclusion: Distinctive characteristics of pediatric phase I trials, in comparison to adult phase I trials, include the necessity for multiinstitutional participation and their higher starting dose (typically 80% of the adult maximum-tolerated dose [MTD]), both of which reflect the relative unavailability of appropriate patients. The application of uniform eligibility criteria and standard definitions for MTD and dose-limiting toxicity (DLT) help to assure that pediatric phase I trials are safely conducted and reliably identify appropriate doses and schedules of agents for phase II evaluation. Where possible, pediatric phase I trials also define the pharmacokinetic behavior of new agents in children.
- Published
- 1998
- Full Text
- View/download PDF
23. Combined continuous infusion etoposide with high-dose cyclophosphamide for refractory neuroblastoma: a phase II study from the Société Française d'Oncologie Pédiatrique.
- Author
-
Méresse V, Vassal G, Michon J, De Cervens C, Courbon B, Rubie H, Perel Y, Landman J, Chastagnier P, and De Valck C
- Subjects
- Adolescent, Antineoplastic Combined Chemotherapy Protocols adverse effects, Child, Child, Preschool, Cyclophosphamide adverse effects, Etoposide adverse effects, Etoposide pharmacokinetics, Female, Humans, Infant, Infusions, Intravenous, Male, Neuroblastoma pathology, Antineoplastic Combined Chemotherapy Protocols administration & dosage, Cyclophosphamide administration & dosage, Etoposide administration & dosage, Neuroblastoma drug therapy
- Abstract
Purpose: Patients older than 1 year with stage IV neuroblastoma who fail to achieve complete remission (CRem) have a particularly poor long-term prognosis. In an attempt to improve the outcome of these refractory patients, we tested a new drug combination., Patients and Methods: Twenty-nine children with advanced neuroblastoma (27 stage IV and two stage III) were entered onto this phase II study. All were refractory to conventional chemotherapy and had measurable disease at the time of the trial. The regimen was a combination of high-dose cyclophosphamide (2 g/m2/d) on days 2, 3, and 4, and etoposide (VP16; 50 mg/m2/d) by continuous intravenous (IV) infusion on days 1 to 5. A pharmacokinetic study of VP16 was conducted in eight patients to determine whether the goal of persistent plasma levels between 1 and 5 micrograms/mL was achieved., Results: Patients received a median of two courses, for a total of 58 courses. The median interval between each course was 32 days. In the 28 assessable patients, the overall response rate was 43%, with one CRem and 11 partial remissions (PRems). No life-threatening complication was observed in these heavily pretreated patients. The median duration of neutropenia (< 5 x 10(9)/L) was 14 days, and that of thrombocytopenia (< 50 x 10(9)/L) was 11 days. The overall incidence of sepsis was 27%. Gastrointestinal toxicity was frequent, but mild. Electrolyte disturbance with antidiuretic hormone (ADH)-like syndrome occurred in eight courses, but resolved rapidly. Grade > or = 2 hemorrhagic cystitis was observed in three courses. No cardiac toxicity was observed. There were no treatment-related deaths. Pharmacokinetic analysis showed that mean steady-state plasma levels (Css) of VP16 were greater than 1 microgram/mL during all the courses., Conclusion: This new drug combination appears to be effective in advanced neuroblastoma. Its toxicity remains manageable, with no life-threatening complications. Further evaluation in patients with less-advanced disease is warranted.
- Published
- 1993
- Full Text
- View/download PDF
24. Juvenile granulosa cell tumor of the ovary in children: a clinical study of 15 cases.
- Author
-
Vassal G, Flamant F, Caillaud JM, Demeocq F, Nihoul-Fekete C, and Lemerle J
- Subjects
- Adolescent, Child, Child, Preschool, Combined Modality Therapy, Female, Granulosa Cell Tumor mortality, Humans, Infant, Neoplasm Recurrence, Local, Neoplasm Staging, Ovarian Neoplasms mortality, Prognosis, Granulosa Cell Tumor therapy, Ovarian Neoplasms therapy
- Abstract
Juvenile granulosa cell tumor (JGCT) in children accounted for 12% of all ovarian tumors treated in the Institut Gustave-Roussy (IGR) Pediatric Department from 1967 to 1985. The median age of the 15 girls was 8 years 7 months (range, 22 months to 15 years 7 months). Precocious pseudopuberty was present in six of the seven girls under 8 years. Of the other seven girls, one developed virilization symptoms. Surgery was the first treatment in each case. According to the Wollner classification, there were six stage I, one stage II, six stage III (including four ruptured tumors), and one stage IV JGCT cases. One patient was not available for staging. An adjuvant treatment (five chemotherapy and one radiotherapy combined with chemotherapy) was administered to six patients. Eleven girls are alive and free of disease, with a median follow-up of 6 years (range, 2 to 18 years). Four girls relapsed 6 to 17 months after surgery and died. Two of these relapses occurred in bone. The prognosis for JGCT in children is favorable for the lower stages when treated with surgery, but the best treatment for extensive and recurrent disease has yet to be determined.
- Published
- 1988
- Full Text
- View/download PDF
Catalog
Discovery Service for Jio Institute Digital Library
For full access to our library's resources, please sign in.